Theseus Pharmaceuticals (THRX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Theseus Pharmaceuticals has successfully completed its merger with Concentra Biosciences, after Concentra’s subsidiary acquired the majority of Theseus’s shares. Shareholders were offered $4.05 per share in cash, plus the opportunity for future payments through a contingent value right. The takeover resulted in Theseus becoming a wholly owned subsidiary of Concentra, leading to the delisting of Theseus’s shares from the Nasdaq and the termination of its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. The transaction, which did not require a stockholder vote, signifies a significant shift in Theseus’s corporate structure and stock market presence.
For further insights into THRX stock, check out TipRanks’ Stock Analysis page.